<DOC>
	<DOCNO>NCT01918475</DOCNO>
	<brief_summary>Carbetocin synthetic analogue hormone Oxytocin routinely use obstetric anesthesiology control uterine bleed cesarean section . As incidental finding , woman receive carbetocin less pain cesarean section woman receive Oxytocin . Carbetocin may therefore analgesic effect . The present study examines analgesic effect use different sensory test , e.g . pressure , heat , cold electrical pain administration carbetocin healthy male volunteer . Any change sensory test might indicative analgesic property carbetocin .</brief_summary>
	<brief_title>Analgesic Effect Oxytocin Receptor Modulation</brief_title>
	<detailed_description>Background Chronic pain still largely unresolved issue , cause suffering , disability high social cost . The search novel pharmacological target therefore priority . A recent study postpartal bleeding come accidental finding possible analgesic action oxytocin agonists carbetocin . Oxytocin well know nonapeptide synthesize hypothalamus , act neurohormone parturition milk ejection reflex . Animal study find descend pathway oxytocin synthetizing neuron project lamina I-II spinal cord , activate subpopulation glutamatergic GABAergic interneurons . In addition GABAergic hyperpolarisation , model oxytocin selectively block A-delta C-fibers publish . Intrathecal administration oxytocin prevents long-term potentiation dorsal horn , think important mechanism enhance central pain processing . Antagonism GABAergic glycinergic neurotransmission mimic many symptom inflammatory neuropathic pain . A loss synaptic inhibition dorsal horn occur animal model experimental pain . Inhibitory synaptic transmission spinal cord dorsal horn use GABA glycine principal fast neurotransmitter . Both open Cl- -channels , induce postsynaptic hyperpolarisation impairs propagation excitatory potential dendrites neuron . Immunofluorescence study reveal abundant glycinergic innervation dorsal horn . According model , inhibitory GABAergic glycinergic interneurons superficial spinal dorsal horn key component control pain transmission periphery brain . The model state non-painful stimulation felt non painful long synaptic GABAergic glycinergic inhibition remain intact . A human study GABAergic modulation pain benzodiazepine recently perform group suggestive analgesic action . However , drug cause sedation addiction , strongly limit clinical usefulness . A pharmacological GABA modulation via oxytocin receptor may attractive alternative , since oxytocin agonist devoid side effect . Quantitative sensory test ( QST ) use explore central process painful stimulus healthy volunteer patient . They base multimodal multi-tissue approach , combine different pain modality apply different tissue order gather sufficient differentiate information human nociceptive system normal pathological condition . QST tool characterize analgesic efficacy carbetocin . Objective We test hypothesis carbetocin produce analgesia healthy volunteer , assess multimodal experimental pain test . Methods Intradermal capsaicin injection volar forearm use create experimental pain hyperalgesia . The area hyperalgesia pinprick brush allodynia quantify , pressure , heat , cold electrical pain threshold well nociceptive withdrawal reflex threshold assess 30 minute capsaicin injection ( baseline assessment ) . Carbetocin 0.1 mg inject intravenously measurement repeat 10 , 60 120 minute . Blood sample take order investigate plasma carbetocin level 10 , 60 120 minute genetic variant oxytocin receptor gene .</detailed_description>
	<mesh_term>Hyperalgesia</mesh_term>
	<mesh_term>Carbetocin</mesh_term>
	<mesh_term>Oxytocin</mesh_term>
	<mesh_term>Analgesics</mesh_term>
	<criteria>male painfree write informed consent Exclusion Criteria chronic pain acute pain time test sign suspicion neurological dysfunction test site intake opioids intake benzodiazepine intake antidepressant intake anticonvulsant intake analgesic drug 48h prior test know allergy carbetocin allergy capsaicin cardiovascular disease asthma bronchiale migraine epilepsy history liver disease history renal disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>randomize control trial</keyword>
	<keyword>placebo control trial</keyword>
	<keyword>cross trial</keyword>
</DOC>